Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
- With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
- Financial Results (for the quarter ending September 30, 2023)
Cash and cash equivalents were $6.4 million. - Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
- The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.